Oligoprogressive castration-resistant prostate cancer treated with metastases-directed stereotactic body radiation therapy: predictive factors for patients’ selection-Reference-Cited by-同舟云学术

Oligoprogressive castration-resistant prostate cancer treated with metastases-directed stereotactic body radiation therapy: predictive factors for patients’ selection

Published:2022-02-21 Issue:3 Volume:39 Page:449-457
ISSN:0262-0898
Container-title:Clinical & Experimental Metastasis
language:en
Short-container-title:Clin Exp Metastasis

Author:

Franzese Ciro^ORCID,Perrino Matteo,Marzo Marco Antonio,Badalamenti Marco,Baldaccini Davide,D’Agostino Giuseppe,Marini Beatrice,De Vincenzo Fabio,Zucali Paolo Andrea,Scorsetti Marta

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s10585-022-10158-7.pdf

Reference31 articles.

1. Hellman S, Weichselbaum RR (1995) Oligometastases. J Clin Oncol 13:8–10. https://doi.org/10.1200/jco.1995.13.1.8

2. Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, DeSouza NM et al (2020) Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol 21:e18-28. https://doi.org/10.1016/S1470-2045(19)30718-1

3. McDonald E, Cheng S, Arciero VS, Saluja R, Zukotynski KA, Cheung P et al (2017) Prevalence of oligoprogressive, metastatic castration-resistant prostate cancer (mCRPC) amenable to stereotactic ablative radiotherapy (SABR) in men undergoing abiraterone acetate (AA) therapy. J Clin Oncol 35:e587–e587. https://doi.org/10.1200/jco.2017.35.6_suppl.e587

4. Hong MKH, Macintyre G, Wedge DC, Van Loo P, Patel K, Lunke S et al (2015) Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer. Nat Commun 6:6605. https://doi.org/10.1038/ncomms7605

5. Gillessen S, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A et al (2020) Management of patients with advanced prostate cancer: report of the Advanced Prostate Cancer Consensus Conference 2019. Eur Urol 77:508–547. https://doi.org/10.1016/j.eururo.2020.01.012

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Stereotactic ablative radiotherapy for oligoprogressive solid tumours: A systematic review and meta-analysis;Radiotherapy and Oncology;2024-11

2. Stereotactic Body Radiotherapy for Oligoprogression in Castration-Resistant Prostate Cancer: Early Toxicity Analysis of the TRAP Trial;Clinical Oncology;2024-09

3. Systematic review of the efficacy of stereotactic ablative radiotherapy for oligoprogressive disease in metastatic cancer;Radiotherapy and Oncology;2024-07

4. The current landscape of stereotactic body radiation therapy for metastatic castration-resistant prostate cancer;Prostate Cancer and Prostatic Diseases;2024-06-19

5. Metastasis-Directed Stereotactic Body Radiotherapy in Prostate Cancer Patients Treated with Systemic Therapy and Undergoing Oligoprogression: Report on 11 Consecutive Cases;Radiation;2024-04-12